查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447724

生物技術合約製造市場評估：按平台類型、產品類型、應用、治療領域和地區劃分的機會和預測（2017-2031）

Biotechnology Contract Manufacturing Market Assessment, By Platform Type, By Product Type, By Application Type, By Therapeutic Area Type, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 238 Pages | 商品交期: 3-5個工作天內

價格

全球生物技術合約製造市場規模將從2023年的176.9億美元增長到2031年的339.7億美元，在2024年至2031年的預測期內複合年增長率為8.5%。預計將增長到美元。

受生物製藥需求增加以及細胞和基因治療技術進步等驅動因素的影響，生物技術合約製造市場預計將成長。 生物製藥性質複雜，需要專門的生產設備，這為製藥公司帶來了管理難度。 在此背景下，製藥公司聘請具有獨特專業知識和製造能力的合約製造組織來滿足市場需求。 不斷擴大的應用領域和對新型細胞和基因療法的需求也正在推動市場擴張。 此外，製造技術的進步以及製藥公司和生物製劑合約製造商之間的合作關係也是市場成長的關鍵驅動力。 然而，生物製品的複雜性以及對專業設施和設備不斷變化的需求對市場成長構成了重大挑戰。 此外，監管的複雜性和限制也限制了市場的成長。 儘管存在這些挑戰和限制因素，預計市場在未來幾年仍將呈指數級增長。

生物製藥的需求不斷增加

由於慢性病的流行、老年人口的增加以及人們對高效、便捷地獲取生物製藥的認識不斷增強，全球對生物製藥的需求正在迅速擴大。 此外，對治療各種疾病的先進生物製藥（例如基因為基礎的生物製藥）的需求不斷增長，也推動了市場的成長。 隨著市場對生物製藥的需求激增，生物技術合約製造的需求預計將進一步增加。 製造商不斷致力於發布新產品並擴大服務，以更好地響應市場需求。

製造技術的進步

製造技術正在改變生物技術合約製造，從而提高效率、增強客製化能力並增強溝通。 自動化、靈活性和增強的供應鏈管理使製造流程更加高效、經濟高效且可靠。 這些進步使合約製造商能夠大量生產高品質的產品並滿足不斷增長的市場需求。 個人化藥物和生物相似藥的進步也提供了進一步的市場吸引力。

基於哺乳動物的平台的優勢

基於哺乳動物細胞的生物技術可生產治療免疫疾病所必需的高品質蛋白質。 這些產品在疾病抗體治療的開發中發揮重要作用，並且比傳統方法具有優勢，例如更高的準確性和更少的副作用。

本報告調查了全球生物技術合約製造市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素、分析、案例研究、競爭格局、以及主要公司的簡介。

目錄

第1章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第4章全球生技合約製造市場展望

  • 市場規模/預測
  • 依平台類型
    • 基於哺乳動物
    • 基於微生物
  • 依產品類型
    • 單株抗體
    • 重組蛋白
    • 疫苗
    • 胰島素
    • 生長因子
    • 幹擾素
    • 其他
  • 依用途
    • 臨床
    • 商業
  • 依治療領域
    • 自體免疫疾病
    • 腫瘤
    • 代謝性疾病
    • 眼科
    • 心血管疾病
    • 傳染病
    • 神經病學
    • 呼吸系統疾病
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲
  • 各公司的市佔率

第5章全球生技合約製造市場展望：按地區

  • 北美
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第 6 章市場映射

  • 依平台類型
  • 依產品類型
  • 依用途
  • 依治療領域
  • 按地區

第7章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 抑制生長的因素（問題/抑制因素）

第 9 章監理架構與創新

  • 專利情況
  • 創新/新興技術

第10章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（主要公司）

第11章價格分析

第 12 章案例研究

第13章主要公司展望

  • Catalent Inc.
  • Lonza Group Ag
  • Patheon N.V. (Thermo Fisher Scientific Inc.)
  • Abzena Plc.
  • Sandoz International GmbH (Novartis AG)
  • Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
  • Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
  • AbbVie Contract Manufacturing (AbbVie Inc.)
  • Samsung Biologics Co. Ltd.
  • Pfizer Centre Source Ltd (Pfizer Inc.)

第 14 章策略建議

第15章關於我們公司/免責聲明

Product Code: MX11131

Global biotechnology contract manufacturing market is projected to witness a CAGR of 8.5% during the forecast period 2024-2031, growing from USD 17.69 billion in 2023 to USD 33.97 billion in 2031. The biotechnology contract manufacturing market is expected to thrive under the influence of driving factors like growing demand for biopharmaceuticals and technical advancements in cell and gene therapies. Biopharmaceutical products are complex in nature and require a specialized manufacturing setup, which is not easy to manage for pharmaceutical firms. In such situations, pharmaceutical companies hire contract manufacturing organizations with exclusive expertise and manufacturing capabilities to cater to the market requirements. The growing application areas and demand for novel cell and gene therapy have significantly induced market expansion. Advancements in manufacturing technologies and collaborations between pharmaceutical companies and biologics contract manufacturers are some other major driving forces for market growth. However, the complexities in the biologics and constantly evolving needs of specialized facilities and equipment are the major growth challenges for the market. Additionally, regulatory complications and restrictions pose restraints on market growth. With regularly evolving technology, the contract manufacturers need to stay updated, which hinders the expansion of key players. Despite all the challenges and restraints, the market is expected to grow exponentially in the future.

In October 2023, with the introduction of Expert'Biome CDMO by Lallemand, the company is bolstering its strategic position in the microbiome space through contract development and production operations. By providing extensive services in the healthcare sector, Lallemand Health Solutions hopes to assist partners in the creation of next-generation strains through Expert'Biome. These services include medicine manufacturing, bioprocess scaling, strain research and development, and other production procedures.

Growing Demand for Biopharmaceuticals

The global demand for biopharmaceuticals is growing rapidly due to the increasing prevalence of chronic diseases, a rising elderly population, and the growing awareness of efficiency and easy access to biopharmaceuticals. The increasing demand for advanced biologic drugs, such as gene-based biopharmaceuticals, to treat various diseases is also fueling market growth. As the market witnesses the surge in demand for biopharmaceuticals, the biotechnology contract manufacturing requirements will rise further, in turn, expanding the market growth. Manufacturers are constantly working on new launches and service expansions to better cater to the market needs.

For instance, in July 2023, Kincell Bio, a CDMO specializing in cell therapies, was officially launched with USD 36 million in funding led by Kineticos Ventures. Kincell is a spinoff of Inceptor Bio's CMC, manufacturing, and quality organizations. With its new funding, Kincell plans to accelerate innovative research and clinical trials. The company has acquired a facility and a team in Gainesville, Florida, and intends to expand in other key markets such as Research Triangle Park, Boston, and other customer locations.

Advancements in Manufacturing Technologies

Manufacturing technologies are driving changes in biotech contract manufacturing, leading to improved efficiency, increased customization, and enhanced communication. Automation, flexibility, and supply chain management enhancements have made the manufacturing process more efficient, cost-effective, and reliable. These advancements enable contract manufacturers to produce high-quality products in large quantities, meeting the growing market demand. The growing advancements in personalized medicines and biosimilars further enhance the market traction. For instance, in November 2023, SwiftPharma, a Belgian biotech company specializing in molecular farming, and PlantForm Corporation, a Canadian biopharmaceutical company, entered into a contract manufacturing agreement. Under this agreement, SwiftPharma will manufacture antibodies and proteins for PlantForm's product pipeline. Notably, PlantForm will have non-exclusive access to SwiftPharma's manufacturing expertise, enabling the production of biosimilar pembrolizumab utilizing PlantForm's unique systems and materials.

Dominance of Mammalian-based Platforms

Mammalian cell-based biotechnology creates high-quality proteins that are essential in treating immunological disorders. These products are key in developing antibody treatments for diseases and offer advantages over older methods, such as increased precision and fewer adverse effects. There is a regulatory shift towards replacing animal components in cell growth media used for mammal-derived biotech products. For instance, in May 2023, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This noteworthy achievement enhances Northway Biotech's reputation as a major force in the field of biopharmaceuticals. The successful 2020 opening of Northway Biotech's process and analytical development laboratories in Waltham, Massachusetts, is the reason for this latest expansion. Modern cGMP suites are now part of the new facility, which is a major turning point in the company's history.

Monoclonal Antibodies Segment Dominates the Market

The demand for monoclonal antibodies has increased significantly, especially during the COVID-19 pandemic, leading to challenges in manufacturing capacity and global shortages of raw materials. To meet this demand, biopharmaceutical companies had to innovate by forming strategic partnerships with contract manufacturing organizations, securing raw materials in advance and collaborating closely with health authorities and government agencies. The demand for these antibodies continues to rise, leading to innovations in manufacturing practices to meet global needs. For instance, in September 2023, KBI Biopharma, a subsidiary of JSR Life Sciences, introduced SUREmAb. This optimized solution uses the SUREtechnology Platform to produce monoclonal antibodies (mAbs) more efficiently and cost-effectively. By utilizing SUREmAb, biopharmaceutical manufacturers can expedite their development timelines. It enables the creation of a research cell bank (RCB) in nine weeks. Additionally, customers can swiftly transition from DNA to GMP drug substance in as little as eleven months. SUREmAb is designed to attain titers of up to 10 g/L, resulting in lower-cost workflow, enhanced operational efficiency, and improved return on investment.

North America to be the Dominating Region

North America leads the biotechnology contract manufacturing due to several factors. The region has a strong pharmaceutical and biotech industry and the presence of highly advanced manufacturing technologies, making it an attractive market for contract manufacturing. Additionally, the rising demand for biologics and biosimilars, increasing outsourcing of biologics manufacturing among biopharmaceutical companies, growing focus on personalized medicines, increasing collaborations between pharmaceutical companies and biologics contract manufacturers, and advancements in manufacturing technologies are driving the growth of the biotechnology contract manufacturing market in North America.

For instance, in January 2024, Enzene Biosciences established its first fabrication facility in the United States, positioned in Hopewell, New Jersey. Scheduled for completion in June 2024, the site has already gained interest from customers, who have started reserving capacities for constant production. The facility, developed to incorporate Enzene Biosciences' patented EnzeneX persistent production technology, is located within the Princeton West Innovation Campus, a strategic area surrounded by biotech and pharmaceutical companies. This location is ideal, enabling Enzene Biosciences to cater to budding US biotechnology firms seeking expertise in continuous manufacturing.

Future Market Scenario

The biopharmaceutical industry has already adjusted its partnerships with suppliers and contract development and manufacturing organizations (CDMOs) to satisfy humanitarian requirements, and this pattern is anticipated to grow. There will be more collaborations between CMOs, biotech startups, and pharmaceutical giants, which will create a strong ecosystem that can speed up the delivery of life-saving treatments to patients worldwide. Additionally, the future of contract manufacturing in the pharmaceutical industry will likely see pharmaceutical companies and CDMOs working more closely together, sharing expertise, resources, and risks to come up with more innovative and effective solutions.

In October 2023, Advent International and Warburg Pincus, prominent global investors, finalized the previously announced acquisition of Baxter International Inc.'s BioPharma Solutions (BPS) business. Operating as an independent contract development and manufacturing organization (CDMO) under the name Simtra BioPharma Solutions, the business will maintain its current range of solutions and capabilities to ensure the continued supply of essential pharmaceutical products worldwide. According to the definitive agreement, Baxter received USD 4.25 billion in cash after factoring in closing adjustments.

Key Players Landscape and Outlook

Catalent Inc., Lonza Group Ag, Patheon N.V. (Thermo Fisher Scientific Inc.), Abzena Plc., Sandoz International GmbH (Novartis AG), Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings), and Baxter Pharmaceutical Solutions LLC are some of the renowned players in the biotechnology contract manufacturing market. These companies play a crucial role in offering specialized services for the manufacturing of biological drugs, particularly biologics, drug substance, and drug product, catering to the needs of pharmaceutical and biotechnological companies globally.

In February 2024, Novo Holdings, a subsidiary of Novo Nordisk, plans to purchase Catalent, a well-established contract manufacturing organization, for USD 16.5 billion. The acquisition will involve Novo Holdings paying USD 63.50 in cash for each outstanding share of Catalent, reflecting a 16.5% increase above the current market value. The transaction is projected to be finalized around the end of 2024.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Biotechnology Contract Manufacturing Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2.By Platform Type
    • 4.2.1.Mammalian-based
    • 4.2.2.Microbial-based
  • 4.3.By Product Type
    • 4.3.1.Monoclonal Antibodies
    • 4.3.2.Recombinant Protein
    • 4.3.3.Vaccine
    • 4.3.4.Insulin
    • 4.3.5.Growth factor
    • 4.3.6.Interferons
    • 4.3.7.Others
  • 4.4.By Application Type
    • 4.4.1.Clinical
    • 4.4.2.Commercial
  • 4.5.By Therapeutic Area Type
    • 4.5.1.Autoimmune Diseases
    • 4.5.2.Oncology
    • 4.5.3.Metabolic Diseases
    • 4.5.4.Ophthalmology
    • 4.5.5.Cardiovascular Diseases
    • 4.5.6.Infectious Diseases
    • 4.5.7.Neurology
    • 4.5.8.Respiratory Disorders
    • 4.5.9.Others
  • 4.6.By Region
    • 4.6.1.North America
    • 4.6.2.Europe
    • 4.6.3.Asia-Pacific
    • 4.6.4.South America
    • 4.6.5.Middle East and Africa
  • 4.7.By Company Market Share (%), 2023

5.Global Biotechnology Contract Manufacturing Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Platform Type
      • 5.1.2.1.Mammalian-based
      • 5.1.2.2.Microbial-based
    • 5.1.3.By Product Type
      • 5.1.3.1.Monoclonal Antibodies
      • 5.1.3.2.Recombinant Protein
      • 5.1.3.3.Vaccine
      • 5.1.3.4.Insulin
      • 5.1.3.5.Growth factor
      • 5.1.3.6.Interferons
      • 5.1.3.7.Others
    • 5.1.4.By Application Type
      • 5.1.4.1.Clinical
      • 5.1.4.2.Commercial
    • 5.1.5.By Therapeutic Area Type
      • 5.1.5.1.Autoimmune Diseases
      • 5.1.5.2.Oncology
      • 5.1.5.3.Metabolic Diseases
      • 5.1.5.4.Ophthalmology
      • 5.1.5.5.Cardiovascular Diseases
      • 5.1.5.6.Infectious Diseases
      • 5.1.5.7.Neurology
      • 5.1.5.8.Respiratory Disorders
      • 5.1.5.9.Others
    • 5.1.6.United States*
      • 5.1.6.1.Market Size & Forecast
      • 5.1.6.1.1.By Value
      • 5.1.6.1.2.By Volume
      • 5.1.6.2.By Platform Type
      • 5.1.6.2.1.Mammalian-based
      • 5.1.6.2.2.Microbial-based
      • 5.1.6.3.By Product Type
      • 5.1.6.3.1.Monoclonal Antibodies
      • 5.1.6.3.2.Recombinant Protein
      • 5.1.6.3.3.Vaccine
      • 5.1.6.3.4.Insulin
      • 5.1.6.3.5.Growth factor
      • 5.1.6.3.6.Interferons
      • 5.1.6.3.7.Others
      • 5.1.6.4.By Application Type
      • 5.1.6.4.1.Clinical
      • 5.1.6.4.2.Commercial
      • 5.1.6.5.By Therapeutic Area Type
      • 5.1.6.5.1.Autoimmune Diseases
      • 5.1.6.5.2.Oncology
      • 5.1.6.5.3.Metabolic Diseases
      • 5.1.6.5.4.Ophthalmology
      • 5.1.6.5.5.Cardiovascular Diseases
      • 5.1.6.5.6.Infectious Diseases
      • 5.1.6.5.7.Neurology
      • 5.1.6.5.8.Respiratory Disorders
      • 5.1.6.5.9.Others
    • 5.1.7.Canada
    • 5.1.8.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Platform Type
  • 6.2.By Product Type
  • 6.3.By Application Type
  • 6.4.By Therapeutic Area Type
  • 6.5.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Patent Landscape
  • 9.2.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Catalent Inc.
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Lonza Group Ag
  • 13.3.Patheon N.V. (Thermo Fisher Scientific Inc.)
  • 13.4.Abzena Plc.
  • 13.5.Sandoz International GmbH (Novartis AG)
  • 13.6.Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
  • 13.7.Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
  • 13.8.AbbVie Contract Manufacturing (AbbVie Inc.)
  • 13.9.Samsung Biologics Co. Ltd.
  • 13.10.Pfizer Centre Source Ltd (Pfizer Inc.)

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 2.Global Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 3.Global Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 4.Global Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 5.Global Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 6.Global Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 7.Global Biotechnology Contract Manufacturing Market Share (%), By Region, 2017-2031F
  • Figure 8.North America Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 9.North America Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 10.North America Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 11.North America Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 12.North America Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 13.North America Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 14.North America Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 15.United States Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 16.United States Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 17.United States Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 18.United States Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 19.United States Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 20.United States Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 21.Canada Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 22.Canada Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 23.Canada Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 24.Canada Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 25.Canada Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 26.Canada Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 27.Mexico Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 28.Mexico Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 29.Mexico Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 30.Mexico Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 31.Mexico Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 32.Mexico Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 33.Europe Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 34.Europe Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 35.Europe Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 36.Europe Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 37.Europe Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 38.Europe Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 39.Europe Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 40.Germany Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 41.Germany Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 42.Germany Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 43.Germany Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 44.Germany Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 45.Germany Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 46.France Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 47.France Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 48.France Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 49.France Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 50.France Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 51.France Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 52.Italy Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 53.Italy Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 54.Italy Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 55.Italy Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 56.Italy Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 57.Italy Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 58.United Kingdom Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 59.United Kingdom Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 60.United Kingdom Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 61.United Kingdom Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 62.United Kingdom Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 63.United Kingdom Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 64.Russia Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 65.Russia Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 66.Russia Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 67.Russia Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 68.Russia Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 69.Russia Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 70.Netherlands Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 71.Netherlands Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 72.Netherlands Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 73.Netherlands Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 74.Netherlands Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 75.Netherlands Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 76.Spain Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 77.Spain Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 78.Spain Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 79.Spain Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 80.Spain Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 81.Spain Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 82.Turkey Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 83.Turkey Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 84.Turkey Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 85.Turkey Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 86.Turkey Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 87.Turkey Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 88.Poland Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 89.Poland Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 90.Poland Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 91.Poland Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 92.Poland Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 93.Poland Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 94.South America Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 95.South America Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 96.South America Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 97.South America Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 98.South America Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 99.South America Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 100.South America Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 101.Brazil Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 102.Brazil Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 103.Brazil Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 104.Brazil Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 105.Brazil Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 106.Brazil Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 107.Argentina Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 108.Argentina Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 109.Argentina Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 110.Argentina Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 111.Argentina Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 112.Argentina Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 113.Asia-Pacific Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 114.Asia-Pacific Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 115.Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 116.Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 117.Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 118.Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 119.Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 120.India Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 121.India Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 122.India Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 123.India Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 124.India Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 125.India Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 126.China Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 127.China Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 128.China Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 129.China Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 130.China Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 131.China Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 132.Japan Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 133.Japan Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 134.Japan Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 135.Japan Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 136.Japan Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 137.Japan Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 138.Australia Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 139.Australia Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 140.Australia Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 141.Australia Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 142.Australia Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 143.Australia Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 144.Vietnam Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 145.Vietnam Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 146.Vietnam Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 147.Vietnam Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 148.Vietnam Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 149.Vietnam Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 150.South Korea Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 151.South Korea Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 152.South Korea Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 153.South Korea Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 154.South Korea Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 155.South Korea Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 156.Indonesia Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 157.Indonesia Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 158.Indonesia Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 159.Indonesia Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 160.Indonesia Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 161.Indonesia Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 162.Philippines Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 163.Philippines Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 164.Philippines Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 165.Philippines Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 166.Philippines Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 167.Philippines Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 168.Middle East & Africa Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 169.Middle East & Africa Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 170.Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 171.Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 172.Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 173.Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 174.Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 175.Saudi Arabia Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 176.Saudi Arabia Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 177.Saudi Arabia Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 178.Saudi Arabia Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 179.Saudi Arabia Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 180.Saudi Arabia Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 181.UAE Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 182.UAE Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 183.UAE Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 184.UAE Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 185.UAE Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 186.UAE Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 187.South Africa Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 188.South Africa Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
  • Figure 189.South Africa Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
  • Figure 190.South Africa Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
  • Figure 191.South Africa Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
  • Figure 192.South Africa Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
  • Figure 193.By Platform Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194.By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195.By Application Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196.By Therapeutic Area Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023